Cash-Rich Stocks: 10x Genomics, Novavax, and Powell Analysis | April 2026 - News and Statistics

FierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B

PharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at home

CellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptation

Endpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye disease

Endpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease study

FierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechs

FierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue

LabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurology

Endpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drug

eLifeAltered cognitive processes shape tactile perception in autism

eLifeCell size modulates ferroptosis susceptibility

Clinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk